Abstract
Aim:
To determine the in vitro and in vivo bioactivity of recombinant human endostatin (rhEndostatin) and to analyze its pharmacokinetics and immunogenicity in rhesus monkeys and patients.
Methods:
The physical chemical characteristics of rhEndostatin were detected according to Pharmacopoeia of the People's Republic of China (2005 edition, part III). Its in vitro and in vivo bioactivities were assayed via proliferation-inhibition on human umbilical vein endothelial cells and their inhibitory effect on tumor-bearing mice models. Serum concentrations of rhEndostatin in monkeys and patients were determined by an enzyme immunoassay method.
Results:
The corresponding specific in vitro activities of rhEndostatin obtained from the cell counting method, 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) assay, and lactate dehydrogenase assay, respectively, were 6.4×107, 6.7×107, and 3.8×108 U/mg, and the in vivo antitumoral potency was 4.04×107 U/mg. In rhesus monkeys, there were no gender differences in all pharmacokinetic parameters. Serum anti-rhEndostatin immunoglobulin (Ig)G antibodies were generated quickly after intravenous (iv) administration and decreased rapidly when therapy was stopped. In phase I clinical trials, linearity in the pharmacokinetics of rhEndostatin was indicated by dose-proportionate increases in the area under the curve and the maximum serum concentration. Serum rhEndostatin reached a steady-state level after 7 d of successive administration with the average concentration at a steady state of 272.44±91.98 ng/mL. Neither IgG nor IgM antibodies against rhEndostatin were observed in patients.
Conclusion:
RhEndostatin exhibited a definite proliferation-inhibition effect on HUVEC, and significant antitumoral activity in mice. The immunoreactivity of rhesus monkeys to rhEndostatin is common, and rhEndostatin showed no immunogenicity in patients in this trial. The results provide a basis for further clinical trials.
Similar content being viewed by others
Article PDF
References
O'Reilly MS, Boehm T, Shing Y, Fukai N, Vasios G, Lane WS, et al. Endostatin: an endogenous inhibitor of angiogenesis and tumor growth. Cell 1997; 88: 277–85.
Ferreras M, Felbor U, Lenhard T, Olsen BR, Delaisse J . Generation and degradation of human endostatin proteins by various proteinases. FEBS Lett 2000; 486: 247–51.
Zhang P, Wu D, Ge J, Zhu Z, Feng G, Yue T, et al. Experimental inhibition of corneal neovascularization by endostatin gene transfec-tion in vivo. Chin Med J (Engl) 2003; 116: 1869–74.
Dhanabal M, Ramchandran R, Volk R, Stillman IE, Lombardo M, Iruela-Arispe ML, et al. Endostatin: yeast production, mutants, and antitumor effect in renal cell carcinoma. Cancer Res 1999; 59: 189–97.
Bloch W, Huggel K, Sasaki T, Grose R, Bugnon P, Addicks K, et al. The angiogenesis inhibitor endostatin impairs blood vessel maturation during wound healing. FASEB J 2000; 14: 2373–6.
Boehm T, Folkman J, Browder T, O'Reilly MS . Antiangiogenic therapy of experimental cancer does not induce acquired drug resistance. Nature 1997; 390: 404–7.
Yin G, Liu W, An P, Li P, Ding I, Planelles V, et al. Endostatin gene transfer inhibits joint angiogenesis and pannus formation in inflammatory arthritis. Mol Ther 2002; 5: 547–54.
Pia N, Pia H, Timo S, Jani L, Ritva H, Ulf-Hakan S, et al. Endostatin inhibits human tongue carcinoma cell invasion and intravasation and blocks the activation of matrix metalloprotease-2, -9, and -13. J Biol Chem 2003; 278: 22 404–11.
Skovseth DK, Veuger MJ, Sorensen DR, Angelis PM, Haraldsen G . Endostatin dramatically inhibits endothelial cell migration, vascular morphogenesis, and perivascular cell recruitment in vivo. Blood 2005; 105: 1044–51.
Davis DW, Shen Y, Mullani NA, Wen S, Herbst RS, O'Reilly M, et al. Quantitative analysis of biomarkers defines an optimal biological dose for recombinant human endostatin in primary human tumors. Clin Cancer Res 2004; 10: 33–42.
Sorensen DR, Read TA, Porwol T, Olsen BR, Timpl R, Sasaki T, et al. Endostatin reduces vascularization, blood flow, and growth in a rat gliosarcoma. Neurooncol 2002; 4: 1–8.
Park JH, Chang KH, Lee JM, Lee YH, Chung IS . Optimal production an in vitro activity of recombinant endostatin from stably transformed Drosophila melanogaster S2 cells. In Vitro Cell Dev Biol Anim 2001; 37: 5–9.
Sim BK, MacDonald NJ, Gubish ER . Angiostatin and endostatin: Endogenous inhibitors of tumor growth. Cancer Metastasis Rev 2000; 19: 181–90.
Huang XJ, Wong MK, Zhao Q, Zhu ZY, Wang KZ, Huang N, et al. Soluble recombinant endostatin purified from Escherichia coli: antiangiogenic activity and antitumor effect. Cancer Res 2001; 61: 478–81.
Sim BK, Fogler WE, Zhou XH, Liang H, Madsen JW, Luu K, et al. Zinc ligand-disrupted recombinant human endostatin: Potent inhibition of tumor growth, safety and pharmacokinetic profile. Angiogenesis 1999; 3: 41–51.
Song HF, Liu XW, Zhang HN, Zhu BZ, Yuan SJ, Liu SY, et al. Pharmacokinetics of His-tag recombinant human endostatin in rhesus monkeys. Acta Pharmacol Sin 2005; 26: 124–8.
Wang JW, Sun Y, Liu YY, Yu QT, Zhang QP, Li K, et al. Results of randomized, multicenter, double-blind phase III trial of rh-endostatin (YH-16) in treatment of advanced non-small cell lung cancer patients. Chi J Lung Cancer 2005; 8: 283–90.
Kulke MH, Bergsland EK, Ryan DP, Enzinger PC, Lynch TJ, Zhu AX, et al. Phase II study of recombinant human endostatin in patients with advanced neuroendocrine tumors. J Clin Oncol 2006; 24: 3555–61.
Bachelot T, Ratel D, Menetrier-Caux C, Wion D, Blay JY, Berger F . Autoantibodies to endostatin in patients with breast cancer: correlation to endostatin levels and clinical outcome. Br J Cancer 2006; 94: 1066–70.
Herbst RS, Mullani NA, Davis DW, Hess KR, McConkey DJ, Charnsangavej C, et al. Development of biologic markers of response and assessment of antiangiogenic activity in a clinical trial of human recombinant endostatin. J Clin Oncol 2002; 20: 3804–14.
Hansma AHG, Broxterman HJ, van der Horst I, Yuana Y, Boven E, Giaccone G, et al. Recombinant human endostatin administered as a 28-day continuous intravenous infusion, followed by daily subcutaneous injections: a phase I and pharmacokinetic study in patients with advanced cancer. Ann Onc 2005; 16: 1695–701.
Eder JP, Supko JG Jr, Clark JW, Puchalski TA, Garcia-Carbonero R, Ryan DP, et al. Phase I clinical trial of recombinant human endostatin administered as a short intravenous infusion repeated daily. J Clin Oncol 2002; 20: 3772–84.
Herbst RS, Hess KR, Tran HT, Tseng JE, Mullani NA, Charnsangavej C, et al. Phase I study of recombinant human endostatin in patients with advanced solid tumors. J Clin Oncol 2002; 20: 3792–803.
Thomas JP, Arzoomanian RZ, Alberti D, Marnocha R, Lee F, Friedl A, et al. Phase I pharmacokinetic and pharmacodynamic study of recombinant human endostatin in patients with advanced solid tumors. J Clin Oncol 2003; 21: 223–31.
Yang L, Wang JW, Tang ZM, Liu XW, Huang J, Li ST, et al. A phase I clinical trial for recombinant human endostatin. Chin J New Drugs 2004; 13: 548–53.
Zhang HY, Han QW, Xu YF, Fan YR, Dai QM, Xu JM, et al. The methods for determining the purity and in vitro or in vivo activity of recombinant human endostatin. Cancer Biol Ther 2005; 4: 207–12.
The State Pharmacopoeia Committee of the People's Republic of China. Pharmacopoeia of the People's Republic of China, part III, 2005 ed. Beijing: Chemical Industry Press; 2005.
Lee Sim BK, O'Reilly MS, Liang H, Fortier AH, He WX, Madsen JW, et al. A recombinant human angiostatin protein inhibits experimental primary and metastatic cancer. Cancer Res 1997; 57: 1329–34.
Xu YF, Zhu LP, Hu B, Rong ZG, Zhu HW, Xu JM, et al. A quantitative method for assessing the antitumor potency of human recombinant endostatin. Eur J Pharmacol 2007; 564: 1–6.
Wei YQ, Wang QR, Zhao X, Yang L, Tian L, Lu Y, et al. Immunotherapy of tumors with xenogeneic endothelial cells as a vaccine. Nat Med 2000; 6: 1160–6.
Tong ZS, Yan Z, Ba Y, Li SF, Shi YH, He LH, et al. Phase I clinical study of recombinant human endostatin. J Chin Modern Med 2006; 3: 1150–5.
Sasaki T, Fukai N, Mann K, Gohring W, Olsen BR, Timpl R . Structure, function and tissue forms of the C-terminal globular domain of collagen XVIII containing the angiogenesis inhibitor endostatin. EMBO J 1998; 17: 4249–56.
Abdollahi A, Hlatky L, Huher P . Endostatin: the logic of anti-angiogenic therapy. Drug Resist Updat 2005; 8: 59–74.
Yamaguchi N, Anand-Apte B, Lee M, Sasaki T, Fukai N, Shapiro R, et al. Endostatin inhibits VEGF-induced endothelial cell migration and tumor growth independently of zinc binding. EMBO J 1999; 18: 4414–23.
Jung SP, Siegrist B, Hornick CA, Wang YZ, Wade MR, Anthony CT, et al. Effect of human recombinant endostatin protein on human angiogenesis. Angiogenesis 2002; 5: 111–8.
Wang YS, Eichler W, Friedrichs U, Yafai Y, Hoffmann S, Yasukawa T, et al. Impact of endostatin on bFGF-induced proliferation, migration, and matrix metalloproteinase-2 expression/secretion of bovine choroidal endothelial cells. Curr Eye Res 2005; 30: 479–89.
McCarty MF, Baker CH, Bucana CD, Fidler IJ . Quantitative and qualitative in vivo angiogenesis assay. Int J Oncol 2002; 21: 5–10.
Li Q, Olsen BR . Increased angiogenic response in aortic explants of collagen XVIII/endostatin-null mice. Am J Pathol 2004; 165: 415–24.
Lee TY, Tjin Tham Sjin RM, Movahedi S, Ahmed B, Pravda EA, Lo KM, et al. Linking antibody Fc domain to endostatin significantly improves endostatin half-life and efficacy. Clin Cancer Res 2008; 14: 1487–93.
Author information
Authors and Affiliations
Corresponding authors
Additional information
This work was supported by the 863 Project from the State Ministry of Science and Technology of China (No 2006AA02Z19E), the 985-II Project from Nanjing University to Gen-xing Xu, the National Natural Science Foundation of China (No 30670671), the Natural Science Foundation of Jiangsu Province, China (No BK2006713), and a Rising Fountain Development Program (RFDP) grant from the State Educational Ministry of China to Jian-jun Wang (No 20050284025).
Rights and permissions
About this article
Cite this article
Hu, B., Zhu, Hw., Zhu, Lp. et al. Bioactivity, pharmacokinetics, and immunogenicity assays in preclinical and clinical trials for recombinant human endostatin. Acta Pharmacol Sin 29, 1357–1369 (2008). https://doi.org/10.1111/j.1745-7254.2008.00865.x
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1111/j.1745-7254.2008.00865.x